Recent developments in the therapeutic targeting of calpains in neurodegeneration

Bibliography

• WELLS GJ, BIHOVSKY R: Calpain inhibitors as potential treatment for stroke and other neurodegenerative diseases: recent trends and developments. Expert Opin. Ther. Patents (1998) 8(12):1707-1727.
   Web of Science ®Google Scholar
• DEPETRILLO PB: Calpains inhibitors – a review of the recent patent literature. Drugs (2002) 5(6):568-576.
   PubMedGoogle Scholar
• CARRAGHER NO: Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr. Pharm. Des. (2006) 12(5):615-638.
   PubMed Web of Science ®Google Scholar
• CAMINS A, VERDAGUER E, FOLCH J, PALLAS M: Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev. (2006) 12(2):135-148.
   PubMedGoogle Scholar
• YUEN PW, WANG KK: Calpain inhibitors: novel neuroprotectants and potential anticataract agents. Drugs Future (1998) 23:741-749.
   Google Scholar
• GOLL DE, THOMPSON VF, LI H, WEI W, CONG J: The calpain system. Physiol. Rev. (2003) 83(3):731-801.
   PubMed Web of Science ®Google Scholar
• CROALL DE, ERSFELD K: The calpains: modular designs and functional diversity. Genome Biol. (2007) 8(6):218.
   PubMed Web of Science ®Google Scholar
• GARCIA DIAZ BE, GAUTHIER S, DAVIES PL: Ca2+ dependency of calpain 3 (p94) activation. Biochemistry (2006) 45(11):3714-3722.
   Google Scholar
• SORIMACHI H, SUZUKI K: The structure of calpain. J. Biochem. (Tokyo) (2001) 129(5):653-664.
   PubMed Web of Science ®Google Scholar
• VAISID T, KOSOWER NS, KATZAV A, CHAPMAN J, BARNOY S: Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse model of Alzheimer's disease. Neurochem. Int. (2007) (In Press).
   Google Scholar
• MOUATT-PRIGENT A, KARLSSON JO, YELNIK J, AGID Y, HIRSCH EC: Calpastatin immunoreactivity in the monkey and human brain of control subjects and patients with Parkinson's disease. J. Comp. Neurol. (2000) 419(2):175-192.
   Google Scholar
• LI J, GRYNSPAN F, BERMAN S, NIXON R, BURSZTAJN S: Regional differences in gene expression for calcium activated neutral proteases (calpains) and their endogenous inhibitor calpastatin in mouse brain and spinal cord. J. Neurobiol. (1996) 30(2):177-191.
   Google Scholar
• GARCIA M, BONDADA V, GEDDES JW: Mitochondrial localization of μ-calpain. Biochem. Biophys. Res. Commun. (2005) 338(2):1241-1247.
   Google Scholar
• HOOD JL, BROOKS WH, ROSZMAN TL: Differential compartmentalization of the calpain/calpastatin network with the endoplasmic reticulum and Golgi apparatus. J. Biol. Chem. (2004) 279(41):43126-43135.
   Google Scholar
• HOOD JL, BROOKS WH, ROSZMAN TL: Subcellular mobility of the calpain/calpastatin network: an organelle transient. Bioessays (2006) 28(8):850-859.
   Google Scholar
• KOH TJ, TIDBALL JG: Nitric oxide inhibits calpain-mediated proteolysis of talin in skeletal muscle cells. Am. J. Physiol. Cell Physiol. (2000) 279(3):C806-C812.
   Google Scholar
• JOHNSON GV: Tau phosphorylation and proteolysis: insights and perspectives. J. Alzheimers Dis. (2006) 9(3 Suppl.):243-250.
   Google Scholar
• XIE HQ, JOHNSON GV: Calcineurin inhibition prevents calpain-mediated proteolysis of tau in differentiated PC12 cells. J. Neurosci. Res. (1998) 53(2):153-164.
   Google Scholar
• LITERSKY JM, JOHNSON GV: Phosphorylation by cAMPdependent protein kinase inhibits the degradation of tau by calpain. J. Biol. Chem. (1992) 267(3):1563-1568.
   PubMed Web of Science ®Google Scholar
• HAWASLI AH, BENAVIDES DR, NGUYEN C et al.: Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat. Neurosci. (2007) 10(7):880-886.
   PubMed Web of Science ®Google Scholar
• WU HY, HSU FC, GLEICHMAN AJ et al.: FYN-mediated phosphorylation of NR2B TYR-1336 controls calpain-mediated NR2B cleavage in neuron and heterologous systems. J. Biol. Chem. (2007) 282(28):20075-20087.
   Google Scholar
• SHEN J, CHANNAVAJHALA P, SELDIN DC, SONENSHEIN GE: Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IκBα. J. Immunol. (2001) 167(9):4919-4925.
   PubMedGoogle Scholar
• PARKER RA, MILLER SJ, GIBSON DM: Phosphorylation of microsomal HMG CoA reductase increases susceptibility to proteolytic degradation in vitro. Biochem. Biophys. Res. Commun. (1984) 125(2):629-635.
   Google Scholar
• SHUSTER CB, HERMAN IM: Indirect association of ezrin with F-actin: isoform specificity and calcium sensitivity. J. Cell Biol. (1995) 128(5):837-848.
   PubMedGoogle Scholar
• HUTTENLOCHER A, PALECEK SP, LU Q et al.: Regulation of cell migration by the calcium-dependent protease calpain. J. Biol. Chem. (1997) 272(52):32719-32722.
   PubMedGoogle Scholar
• SCHOLLMEYER JE: Calpain II involvement in mitosis. Science (1988) 240(4854):911-913.
   PubMed Web of Science ®Google Scholar
• SIMAN R, BAUDRY M, LYNCH G: Regulation of glutamate receptor binding by the cytoskeletal protein fodrin. Nature (1985) 313(5999):225-228.
   PubMed Web of Science ®Google Scholar
• VINADE L, PETERSEN JD, DO K, DOSEMECI A, REESE TS: Activation of calpain may alter the postsynaptic density structure and modulate anchoring of NMDA receptors. Synapse (2001) 40(4):302-309.
   Google Scholar
• LU X, WYSZYNSKI M, SHENG M, BAUDRY M: Proteolysis of glutamate receptor-interacting protein by calpain in rat brain: implications for synaptic plasticity. J. Neurochem. (2001) 77(6):1553-1560.
   Google Scholar
• DEL BELLO B, MORETTI D, GAMBERUCCI A, MAELLARO E: Cross-talk between calpain and caspase-3/-7 in cisplatin-induced apoptosis of melanoma cells: a major role of calpain inhibition in cell death protection and p53 status. Oncogene (2007) 26(19):2717-2726.
   Google Scholar
• NEUMAR RW, XU YA, GADA H, GUTTMANN RP, SIMAN R: Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. J. Biol. Chem. (2003) 278(16):14162-14167.
   PubMed Web of Science ®Google Scholar
• NAKAGAWA T, YUAN J: Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J. Cell Biol. (2000) 150(4):887-894.
   PubMed Web of Science ®Google Scholar
• WANG KK, POSMANTUR R, NADIMPALLI R et al.: Caspase-mediated fragmentation of calpain inhibitor protein calpastatin during apoptosis. Arch. Biochem. Biophys. (1998) 356(2):187-196.
   PubMed Web of Science ®Google Scholar
• YOUSEFI S, PEROZZO R, SCHMID I et al.: Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat. Cell Biol. (2006) 8(10):1124-1132.
   PubMed Web of Science ®Google Scholar
• DEMARCHI F, BERTOLI C, COPETTI T et al.: Calpain is required for macroautophagy in mammalian cells. J. Cell Biol. (2006) 175(4):595-605.
   PubMed Web of Science ®Google Scholar
• MISHIZEN-EBERZ AJ, GUTTMANN RP, GIASSON BI et al.: Distinct cleavage patterns of normal and pathologic forms of α-synuclein by calpain I in vitro. J. Neurochem. (2003) 86(4):836-847.
   PubMedGoogle Scholar
• PAIK SR, LEE JH, KIM DH, CHANG CS, KIM J: Aluminum-induced structural alterations of the precursor of the non-Aβ component of Alzheimer's disease amyloid. Arch. Biochem. Biophys. (1997) 344(2):325-334.
   PubMed Web of Science ®Google Scholar
• KIM HJ, LEE D, LEE CH et al.: Calpain-resistant fragment(s) of α-synuclein regulates the synuclein-cleaving activity of 20S proteasome. Arch. Biochem. Biophys. (2006) 455(1):40-47.
   Google Scholar
• REN QG, LIAO XM, CHEN XQ, LIU GP, WANG JZ: Effects of tau phosphorylation on proteasome activity. FEBS Lett. (2007) 581(7):1521-1528.
   Google Scholar
• CHEN Q, WANG S, THOMPSON SN, HALL ED, GUTTMANN RP: Identification and characterization of PEBP as a calpain substrate. J. Neurochem. (2006) 99(4):1133-1141.
   Google Scholar
• CUERRIER D, MOLDOVEANU T, INOUE J, DAVIES PL, CAMPBELL RL: Calpain inhibition by α-ketoamide and cyclic hemiacetal inhibitors revealed by X-ray crystallography. Biochemistry (2006) 45(24):7446-7452.
   PubMed Web of Science ®Google Scholar
• MOLDOVEANU T, CAMPBELL RL, CUERRIER D, DAVIES PL: Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site. J. Mol. Biol. (2004) 343(5):1313-1326.
   PubMed Web of Science ®Google Scholar
• LIN GD, CHATTOPADHYAY D, MAKI M et al.: Crystal structure of calcium bound domain VI of calpain at 1.9 A resolution and its role in enzyme assembly, regulation, and inhibitor binding. Nat. Struct. Biol. (1997) 4(7):539-547.
   PubMedGoogle Scholar
• BLANCHARD H, LI Y, CYGLER M et al.: Ca(2+)-binding domain VI of rat calpain is a homodimer in solution: hydrodynamic, crystallization and preliminary X-ray diffraction studies. Protein Sci. (1996) 5(3):535-537.
   Google Scholar
• NIXON RA: Calcium-activated neutral proteinases as regulators of cellular function. Implications for Alzheimer's disease pathogenesis. Ann. NY Acad. Sci. (1989) 568:198-208.
   PubMedGoogle Scholar
• NILSSON E, ALAFUZOFF I, BLENNOW K et al.: Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue. Neurobiol. Aging (1990) 11(4):425-431.
   Google Scholar
• SAITO K, ELCE JS, HAMOS JE, NIXON RA: Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer's disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. USA (1993) 90(7):2628-2632.
   PubMed Web of Science ®Google Scholar
• CROCKER SJ, SMITH PD, JACKSON-LEWIS V et al.: Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci. (2003) 23(10):4081-4091.
   PubMed Web of Science ®Google Scholar
• DUFTY BM, WARNER LR, HOU ST et al.: Calpain-cleavage of α-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. (2007) 170(5):1725-1738.
   PubMed Web of Science ®Google Scholar
• ALVIRA D, TAJES M, VERDAGUER E et al.: Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J. Pineal Res. (2006) 40(3):251-258.
   PubMed Web of Science ®Google Scholar
• KIM YJ, YI Y, SAPP E et al.: Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl. Acad. Sci. USA (2001) 98(22):12784-12789.
   Google Scholar
• GAFNI J, ELLERBY LM: Calpain activation in Huntington's disease. J. Neurosci. (2002) 22(12):4842-4849.
   PubMed Web of Science ®Google Scholar
• YADAVALLI R, GUTTMANN RP, SEWARD T et al.: Calpain-dependent endoproteolytic cleavage of PrPSc modulates scrapie prion propagation. J. Biol. Chem. (2004) 279(21):21948-21956.
   PubMed Web of Science ®Google Scholar
• SAATMAN KE, MURAI H, BARTUS RT et al.: Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc. Natl. Acad. Sci. USA (1996) 93(8):3428-3433.
   PubMed Web of Science ®Google Scholar
• ARRIGONI E, COHADON F: Calcium-activated neutral protease activities in brain trauma. Neurochem. Res. (1991) 16(4):483-487.
   Google Scholar
• LI Z, HOGAN EL, BANIK NL: Role of calpain in spinal cord injury: increased mcalpain immunoreactivity in spinal cord after compression injury in the rat. Neurochem. Int. (1995) 27(4-5):425-432.
   Google Scholar
• SHIELDS DC, TYOR WR, DEIBLER GE, HOGAN EL, BANIK NL: Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. USA (1998) 95(10):5768-5772.
   PubMedGoogle Scholar
• KERLERO DE ROSBO N, CARNEGIE PR, BERNARD CC: Quantitative electroimmunoblotting study of the calcium-activated neutral protease in human myelin. J. Neurochem. (1986) 47(4):1007-1012.
   Google Scholar
• KRAMEROVA I, BECKMANN JS, SPENCER MJ: Molecular and cellular basis of calpainopathy (limb girdle muscular dystrophy type 2A). Biochim. Biophys. Acta (2007) 1772(2):128-144.
   Google Scholar
• FANIN M, NASCIMBENI AC, FULIZIO L et al.: Loss of calpain-3 autocatalytic activity in LGMD2A patients with normal protein expression. Am. J. Pathol. (2003) 163(5):1929-1936.
   PubMed Web of Science ®Google Scholar
• SUGITA H, ISHIURA S, SUZUKI K, IMAHORI K: Ca-activated neutral protease and its inhibitors: in vitro effect on intact myofibrils. Muscle Nerve (1980) 3(4):335-339.
   Web of Science ®Google Scholar
• GUTTMANN RP, ELCE JS, BELL PD, ISBELL JC, JOHNSON GV: Oxidation inhibits substrate proteolysis by calpain I but not autolysis. J. Biol. Chem. (1997) 272(3):2005-2012.
   PubMed Web of Science ®Google Scholar
• GUTTMANN RP, JOHNSON GV: Oxidative stress inhibits calpain activity in situ. J. Biol. Chem. (1998) 273(21):13331-13338.
   PubMed Web of Science ®Google Scholar
• WANG KK, NATH R, POSNER A et al.: An α-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc. Natl. Acad. Sci. USA (1996) 93(13):6687-6692.
   PubMed Web of Science ®Google Scholar
• RAMI A, FERGER D, KRIEGLSTEIN J: Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity. Neurosci. Res. (1997) 27(1):93-97.
   PubMed Web of Science ®Google Scholar
• BANIK NL, SHIELDS DC, RAY S et al.: Role of calpain in spinal cord injury: effects of calpain and free radical inhibitors. Ann. NY Acad. Sci. (1998) 844:131-137.
   PubMed Web of Science ®Google Scholar
• KUPINA NC, NATH R, BERNATH EE et al.: The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. J. Neurotrauma (2001) 18(11):1229-1240.
   PubMed Web of Science ®Google Scholar
• HASSEN GW, FELIBERTI J, KESNER L, STRACHER A, MOKHTARIAN F: A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. J. Neuroimmunol. (2006) 180(1-2):135-146.
   Google Scholar
• SORIMACHI Y, HARADA K, YOSHIDA K: Involvement of calpain in postmortem proteolysis in the rat brain. Forensic Sci. Int. (1996) 81(2-3):165-174.
   Google Scholar
• KOOHMARAIE M: The role of Ca(2+)-dependent proteases (calpains) in post mortem proteolysis and meat tenderness. Biochimie (1992) 74(3):239-245.
   PubMed Web of Science ®Google Scholar
• TANDON A, YU H, WANG L et al.: Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles. J. Neurochem. (2003) 86(3):572-581.
   PubMedGoogle Scholar
• GRYNSPAN F, GRIFFIN WR, CATALDO A, KATAYAMA S, NIXON RA: Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res. (1997) 763(2):145-158.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI T, HAASS C, SAIDO TC, OMURA S, IHARA Y: Specific increase in amyloid β-protein 42 secretion ratio by calpain inhibition. Biochemistry (1997) 36(27):8377-8383.
   PubMed Web of Science ®Google Scholar
• KLAFKI HW, PAGANETTI PA, SOMMER B, STAUFENBIEL M: Calpain inhibitor I decreases βA4 secretion from human embryonal kidney cells expressing β-amyloid precursor protein carrying the APP670/671 double mutation. Neurosci. Lett. (1995) 201(1):29-32.
   PubMed Web of Science ®Google Scholar
• ZHANG L, SONG L, PARKER EM: Calpain inhibitor I increases β-amyloid peptide production by inhibiting the degradation of the substrate of γ-secretase. Evidence that substrate availability limits β-amyloid peptide production. J. Biol. Chem. (1999) 274(13):8966-8972.
   Google Scholar
• MARCUM JL, MATHENIA JK, CHAN R, GUTTMANN RP: Oxidation of thiol-proteases in the hippocampus of Alzheimer's disease. Biochem. Biophys. Res. Commun. (2005) 334(2):342-348.
   PubMedGoogle Scholar
• NEFFE AT, ABELL AD: Developments in the design and synthesis of calpain inhibitors. Curr. Opin Drug Discov. Dev. (2005) 8(6):684-700.
   PubMedGoogle Scholar
• WANG KK: Calpain and caspase: can you tell the difference? Trends Neurosci. (2000) 23(1):20-26.
   PubMed Web of Science ®Google Scholar
• GRAYBILL TL, DOLLE RE, OSIFO IK et al.: Inhibition of human erythrocyte calpain I by novel quinolinecarboxamides. Bioorg. Med. Chem. Lett. (1995) 5(4):387-392.
   Google Scholar
• GUTTMANN RP, DAY GA III, WANG X, BOTTIGGI KA: Identification of a novel calpain inhibitor using phage display. Biochem. Biophys. Res. Commun. (2005) 333(4):1087-1092.
   PubMed Web of Science ®Google Scholar
• HANNA RA, GARCIA-DIAZ BE, DAVIES PL: Calpastatin simultaneously binds four calpains with different kinetic constants. FEBS Lett. (2007) 581(16):2894-2898.
   PubMed Web of Science ®Google Scholar
• GUTTMANN RP, JOHNSON GV: Calpain-mediated proteolysis of neuronal structural proteins. In: Calpain: Pharmacology and Toxicology of Calcium-Dependent Protease. Wang KK, Yuen PW (Eds), Taylor and Francis, Philadelphia, USA (1999):229-249.
   Google Scholar
• GUTTMANN RP, BAKER DL, SEIFERT KM et al.: Specific proteolysis of the NR2 subunit at multiple sites by calpain. J. Neurochem. (2001) 78(5):1083-1093.
   Google Scholar
• BANOCZI Z, TANTOS A, FARKAS A et al.: Synthesis of cell-penetrating conjugates of calpain activator peptides. Bioconjug. Chem. (2007) 18(1):130-137.
   PubMed Web of Science ®Google Scholar
• AUVIN S, PIGNOL B, NAVET E et al.: Novel dual inhibitors of calpain and lipid peroxidation. Bioorg. Med. Chem. Lett. (2004) 14(14):3825-3828.
   PubMed Web of Science ®Google Scholar
• PIGNOL B, AUVIN S, CARRE D, MARIN JG, CHABRIER PE: Calpain inhibitors and antioxidants act synergistically to prevent cell necrosis: effects of the novel dual inhibitors (cysteine protease inhibitor and antioxidant) BN 82204 and its pro-drug BN 82270. J. Neurochem. (2006) 98(4):1217-1228.
   PubMed Web of Science ®Google Scholar
• AUVIN S, PIGNOL B, NAVET E et al.: Novel dual inhibitors of calpain and lipid peroxidation with enhanced cellular activity. Bioorg. Med. Chem. Lett. (2006) 16(6):1586-1589.
   PubMed Web of Science ®Google Scholar
• WAN W, DEPETRILLO PB: Ritonavir inhibition of calcium-activated neutral proteases. Biochem. Pharmacol. (2002) 63(8):1481-1484.
   PubMed Web of Science ®Google Scholar
• CUERRIER D, NIE Z, BADLEY AD, DAVIES PL: Ritonavir does not inhibit calpain in vitro. Biochem. Biophys. Res. Commun. (2005) 327(1):208-211.
   PubMed Web of Science ®Google Scholar
• MELLGREN RL, MERICLE MT, LANE RD: Proteolysis of the calcium-dependent protease inhibitor by myocardial calcium-dependent protease. Arch. Biochem. Biophys. (1986) 246(1):233-239.
   PubMedGoogle Scholar
• SALVESEN G, PARKES C, ABRAHAMSON M, GRUBB A, BARRETT AJ: Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem. J. (1986) 234(2):429-434.
   PubMed Web of Science ®Google Scholar
• PAVORD S, KELTON JG, WARNER MN et al.: Proteolytic degradation of high molecular weight kininogen in acute thrombotic thrombocytopenic purpura. Br. J. Haematol. (1997) 97(4):762-767.
   Google Scholar